Search Result

Results for "

P300/CBP inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (5) CTLA-4 (1) Discoidin Domain Receptor (1) Epigenetic Reader Domain (42) Fungal (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (51) Histone Demethylase (1) IFNAR (1) IKZF Family (1) LAG-3 (1) Ligands for Target Protein for PROTAC (2) NF-κB (1) PARP (1) PD-1/PD-L1 (1) PROTACs (8) Reference Standards (4) Sirtuin (1) STAT (1) STING (1) VEGFR (1) Wnt (2) β-catenin (3)
By Research Areas:	Cancer (75) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (2)

By Targets:

Androgen Receptor (1)

Apoptosis (5)

CTLA-4 (1)

Discoidin Domain Receptor (1)

Epigenetic Reader Domain (42)

Fungal (1)

HIF/HIF Prolyl-Hydroxylase (2)

Histone Acetyltransferase (51)

Histone Demethylase (1)

IFNAR (1)

IKZF Family (1)

LAG-3 (1)

Ligands for Target Protein for PROTAC (2)

NF-κB (1)

PARP (1)

PD-1/PD-L1 (1)

PROTACs (8)

Reference Standards (4)

Sirtuin (1)

STAT (1)

STING (1)

VEGFR (1)

Wnt (2)

β-catenin (3)

By Research Areas:

Cancer (75)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107455

A-485 Maximum Cited Publications 99 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485, a chemical probe, is a potent and selective catalytic inhibitor of *p300/CBP* with IC₅₀s of 9.8 nM and 2.6 nM for *p300* and *CBP* histone acetyltransferase (HAT), respectively .

HY-111784

Inobrodib 10+ Cited Publications CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .

HY-14428

ICG-001 60+ Cited Publications	β-catenin Apoptosis	Cancer
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC₅₀ of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.

HY-15826

SGC-CBP30 15+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for *CBP* and *p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)]* bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-100726

GNE-272 5 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
GNE-272 is a potent and selective *CBP/EP300* inhibitor with IC₅₀ values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300 .

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for *CBP/p300, with DC₅₀* of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-136938

NEO2734 4 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-19541

I-CBP112 5 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112, a chemical probe, is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-124696

PU139 4 Publications Verification	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .

HY-100482

CPI-637 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent *CBP/EP300* bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for *CBP, EP300* and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for *CBP* .

HY-111422

PLX51107 3 Publications Verification	Epigenetic Reader Domain	Cancer
PLX51107 is a potent and selective BET inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).

HY-141546

Pocenbrodib	Histone Acetyltransferase	Cancer
Pocenbrodib is a *P300/CBP* inhibitor. Pocenbrodib blocks the function of *P300/CBP* and inhibits the acetylation of histones and non-histone proteins. Pocenbrodib may be used in research related to castration-resistant prostate cancer and other cancers .

HY-101125

L-Moses 2 Publications Verification L-45	Epigenetic Reader Domain	Cancer
L-Moses (L-45), a chemical probe, is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active *CBP/p300* PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

HY-154984

JET-209	Histone Acetyltransferase PROTACs	Cancer
JET-209 is a potent CBP/p300 PROTAC degrader, with DC₅₀ values of 0.05 nM and 0.2 nM for *CBP* and *p300. JET-209 demonstrates remarkable anti-tumor activity against various acute leukemia cell lines and effectively inhibits* tumor growth in xenograft tumor models. JET-209 can be used for the study of acute leukemia .

HY-128876

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-132197

CBP/p300-IN-12 1 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and *CBP* inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-115539

Windorphen	Wnt β-catenin Histone Acetyltransferase	Cancer
Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets *p300, disrupting the association of the mammalian β-catenin with p300* but not CBP .

HY-112359

C-82	β-catenin Wnt	Cancer
C-82 is a second-generation specific *CBP/β-catenin* antagonist, which inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300 .

HY-152241

DS-9300	Histone Acetyltransferase	Cancer
DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC₅₀ value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research .

HY-139108

DCH36_06	Histone Acetyltransferase Apoptosis	Cancer
DCH36_06 is a potent and selective *p300/CBP* inhibitor with IC₅₀s of 0.6 μM and 3.2 μM for *p300* and *CBP, respectively. DCH36_06 mediated p300/CBP* inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .

HY-139148

UMB298	Epigenetic Reader Domain	Cancer
UMB298 is a potent and selective *CBP/P300* bromodomain inhibitor .

HY-17663

KMR-206	PARP STAT STING IFNAR	Cancer
KMR-206 is a PARP7 inhibitor with an IC₅₀ of 13.7 nM. KMR-206 relieves AHR-mediated transcriptional repression and enhances CYP1A1 expression in the presence of TCDD. KMR-206 induces the STING-dependent IFN-β signaling pathway and increases the levels of STAT1, pSTAT1 and nuclear PARP7 in cancer cells. KMR-206 reduces the viability of lung adenocarcinoma cells, enhances radiation-induced immunogenic signals, and induces the production of immunogenic signals in glioblastoma cancer stem cells. KMR-206 destabilizes FRA1 to increase IRF1 levels and promotes the *IRF3-CBP/p300* interaction. KMR-206 can be used in studies related to lung adenocarcinoma and glioblastoma .

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC₅₀ values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .

HY-162259

QC-182	PROTACs Histone Acetyltransferase	Cancer
QC-182 is a potent PROTAC degrader of *p300/CBP. QC-182 reduces p300* protein in the SK-HEP-1 cells (DC₅₀ = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC₅₀ values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC) .

HY-110263

EML 425 2 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cardiovascular Disease Neurological Disease Metabolic Disease
EML425 is a potent and selective CREB binding protein (CBP)/p300 inhibitor with IC₅₀s of 2.9 and 1.1 μM, respectively.

HY-161483

CBP/p300 ligand 3	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). *CBP* and *p300* are two proteins with histone acetyltransferase (HAT) activity, and *CBP* and *p300* play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀ of 18.8 nM .

HY-100697

TPOP146 3 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
TPOP146 is a selective *CBP/P300* benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.

HY-124722

OHM1	HIF/HIF Prolyl-Hydroxylase	Cancer
OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM .

HY-147290

NSC 694623	Histone Acetyltransferase	Cancer
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer .

HY-146277

CBP/p300-IN-19	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .

HY-146277A

CBP/p300-IN-19 hydrochloride	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .

HY-176251

CBP/p300-IN-22	Histone Acetyltransferase Epigenetic Reader Domain NF-κB	Inflammation/Immunology Cancer
CBP/p300-IN-22 is a selective *CBP/EP300-BRD* inhibitor with an IC₅₀ of 4 nM. CBP/p300-IN-22 is highly selective over BRD4(1). CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions.

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-139861

CBP/p300-IN-14	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of *CBP/EP300* (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-101125A

L-Moses dihydrochloride 2 Publications Verification L-45 dihydrochloride	Epigenetic Reader Domain	Cancer
L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-160260

EP300/CBP-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
EP300/CBP-IN-1 (compound 172) is a potent *EP300/CBP* inhibitor with IC₅₀s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .

HY-19541A

I-CBP112 hydrochloride	Epigenetic Reader Domain	Cancer
I-CBP112 hydrochloride is a selective inhibitor of *CBP/P300* that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .

HY-151812

CBP/p300-IN-20	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
CBP/p300-IN-20 is a potent and selective *p300/CBP* inhibitor, with a pIC₅₀ of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer .

HY-155229

CBP/p300-IN-21	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-21 (Compound 5d) is a selective *CBP/p300* inhibitor (IC₅₀: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice .

HY-161958

dCE-2	PROTACs Histone Acetyltransferase	Cancer
dCE-2 (compound 5) is a PROTAC targeting CREB binding protein (CBP) and E1A-associated protein (EP300), which was developed based on the crystal structure of bromodomain (BRD) inhibitors. dCE-2 is composed of E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), PROTAC Linker tert-Butyl 11-aminoundecanoate (HY-130715) (black part) and PROTAC target protein ligand EP300/CBP ligand 2 (HY-161960) (red part), of which the target protein ligand activity control is EP300/CBP ligand 1 (HY-161959), and the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C10-Boc (HY-161961) ^{[1] ^.}

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent *p300/CBP* inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-123758

XDM-CBP	Epigenetic Reader Domain	Cancer
XDM-CBP is a *CBP/p300* inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

Cat. No.	Product Name	Target	Research Area

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

HY-P11829

ACTR-AD1 2L	Histone Acetyltransferase	Cancer
ACTR-AD1 2L is a ACTR-AD1 peptide. ACTR-AD1 2L inhibits *CBP/p300-NCOA3* complex formation, modulates gene transcription, inhibits CBP/p300 acetylase activity, reduces acetylation levels, and exhibits antiproliferative activity. ACTR-AD1 2L binds with stronger affinity to its target proteins than the wild-type peptide. ACTR-AD1 2L can be used for the research of breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: